GBA Presents: RADIO SAVANT-!

valarietan.jpg

Valarie Tan is a reporter for Bloomberg



1369377882_92914.jpg


1. Hilary Rowland


The 33-year old self-taught programmer is the CEO of eClick

Hilary Rowland

(I don't think Mary can do this)
Position:CEO of eClick Interactive Inc and NewFaces.com

The sexy Hilary Rowland is the head of Project Migration in eClick Interactive Inc. This 33-year old is a self-taught programmer that set foot in the business world at the quite young age 15. She is a great charity worker too. She is known to have sold her jewelry designs to eliminate poverty in Africa.:D
 
stonedinvestor said:
valarietan.jpg

Valarie Tan is a reporter for Bloomberg



1369377882_92914.jpg


1. Hilary Rowland


The 33-year old self-taught programmer is the CEO of eClick

Hilary Rowland

(I don't think Mary can do this)
Position:CEO of eClick Interactive Inc and NewFaces.com

The sexy Hilary Rowland is the head of Project Migration in eClick Interactive Inc. This 33-year old is a self-taught programmer that set foot in the business world at the quite young age 15. She is a great charity worker too. She is known to have sold her jewelry designs to eliminate poverty in Africa.:D
More...
All former lovers of the Savant, I envy him!!!!!!
 
TrailerParkTed said:
It’s in my Robinhood account, it’s a anti-pureneric autism and spectrum drug developer. Highly volatile. Why is ISEE going nuts?
More...
Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy


IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for avacincaptad pegol (ACP, also known as Zimura®), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD). To date, ACP is the first and only investigational therapy to receive Breakthrough Therapy designation status for this indication, which was granted based on the 12-month pre-specified primary endpoint data in the GATHER1 and GATHER2 pivotal clinical trials.

Breakthrough Therapy designation is designed to accelerate the development and regulatory review of potential new medicines that are intended to treat a serious condition and address a significant unmet medical need. The new medicine needs to show preliminary clinical evidence that the drug may demonstrate substantial improvement in effectiveness or safety over available therapies on a clinically significant endpoint and in general, should show a clear advantage.1

“We believe this Breakthrough designation reflects the fact that both GATHER1 and GATHER2 met their primary endpoint with a safety profile that meets the stringent criteria required,” said Glenn P. Sblendorio, Chief Executive Officer of Iveric Bio. “We are now focused on the execution of our full NDA submission and launch preparation, with the possibility of being first to market. We look forward to working collaboratively with the FDA to expedite the review timeline for avacincaptad pegol and to potentially bringing a new therapy to AMD patients impacted by GA.”
 
TrailerParkTed said:
It’s in my Robinhood account, it’s a anti-pureneric autism and spectrum drug developer. Highly volatile. Why is ISEE going nuts?
More...




Iveric bio announces FDA granted breakthrough designation for Zimura 16:04 ISEE IVERIC bio "announced that the FDA has granted Breakthrough Therapy designation for avacincaptad pegol - ACP, also known as Zimura - a novel investigational complement C5 inhibitor for the treatment of geographic atrophy secondary to Age-Related Macular Degeneration. To date, ACP is the first and only investigational therapy to receive Breakthrough Therapy designation status for this indication, which was granted based on the 12-month pre-specified primary endpoint data in the GATHER1 and GATHER2 pivotal clinical trials." Glenn P. Sblendorio, CEO, says: "We believe this Breakthrough designation reflects the fact that both GATHER1 and GATHER2 met their primary endpoint with a safety profile that meets the stringent criteria required. We are now focused on the execution of our full NDA submission and launch preparation, with the possibility of being first to market. We look forward to working collaboratively with the FDA to expedite the review timeline for avacincaptad pegol and to potentially bringing a new therapy to AMD patients impacted by GA."
 
stonedinvestor said:
GBA gummy no 2--

WKEY WISeKey International Holding AG
$1.700.07(+4.47%)10:42 AM 11/17/22
NASDAQ |$USD |Pre-Market:$1.87+0.17(+9.82%)<---------- wait for retrace.

WISeKey sees FY22 semiconductor revenue to $22.7M; FY23 revenues expected to grow over 40% Y/Y
More...


INITIATE GUMMY! GO TIME!

LONG WISEKEY $1.65



Correction- $1.85.
 
Last edited:
You must log in or register to reply here.
Back
Top